Novavax, Inc. (NVAX)
10.32
+0.20
(+1.93%)
USD |
NASDAQ |
Sep 02, 16:00
10.33
+0.02
(+0.15%)
After-Hours: 19:41
Novavax Research and Development Expense (TTM) : 335.42M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 335.42M |
| March 31, 2026 | 345.26M |
| December 31, 2025 | 338.72M |
| September 30, 2025 | 369.02M |
| June 30, 2025 | 354.21M |
| March 31, 2025 | 383.23M |
| December 31, 2024 | 386.97M |
| September 30, 2024 | 447.39M |
| June 30, 2024 | 470.65M |
| March 31, 2024 | 580.78M |
| December 31, 2023 | 735.20M |
| September 30, 2023 | 828.36M |
| June 30, 2023 | 1.026B |
| March 31, 2023 | 1.099B |
| December 31, 2022 | 1.235B |
| September 30, 2022 | 1.940B |
| June 30, 2022 | 2.044B |
| March 31, 2022 | 2.325B |
| December 31, 2021 | 2.535B |
| September 30, 2021 | 1.973B |
| June 30, 2021 | 1.859B |
| March 31, 2021 | 1.323B |
| December 31, 2020 | 747.03M |
| September 30, 2020 | 375.17M |
| June 30, 2020 | 99.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 95.26M |
| December 31, 2019 | 113.84M |
| September 30, 2019 | 127.92M |
| June 30, 2019 | 150.63M |
| March 31, 2019 | 164.76M |
| December 31, 2018 | 173.80M |
| September 30, 2018 | 180.04M |
| June 30, 2018 | 180.58M |
| March 31, 2018 | 175.30M |
| December 31, 2017 | 168.44M |
| September 30, 2017 | 169.88M |
| June 30, 2017 | 181.00M |
| March 31, 2017 | 206.64M |
| December 31, 2016 | 237.94M |
| September 30, 2016 | 262.74M |
| June 30, 2016 | 237.68M |
| March 31, 2016 | 197.82M |
| December 31, 2015 | 154.75M |
| September 30, 2015 | 109.34M |
| June 30, 2015 | 100.64M |
| March 31, 2015 | 90.80M |
| December 31, 2014 | 79.43M |
| September 30, 2014 | 65.26M |
| June 30, 2014 | 59.99M |
| March 31, 2014 | 55.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.635B |
| Merck & Co., Inc. | 27.26B |
| Pfizer Inc. | 10.82B |
| Recursion Pharmaceuticals, Inc. | 344.11M |
| Agenus, Inc. | 57.69M |